Key result
Dihydropyridines show potential protective effects when repurposed for Alzheimer's and Parkinson's diseases.
Why the study?
The specific molecular mechanisms regulating Cav1.2 channel activity remain incompletely understood, and better knowledge of channel modulation is needed to develop improved therapeutic strategies for neurodegenerative diseases.
Post-translational modifications of the Cav1.2 calcium channel are implicated in neurodegenerative diseases, highlighting the potential of repurposing cardiovascular dihydropyridine drugs for Alzheimer's and Parkinson's diseases.
Hypothesis-generating for dihydropyridine repurposing in neurodegeneration; leaves open clinical translation without randomized data.
Cav1.2 plays an essential role in learning and memory, drug addiction, and neuronal development. Intracellular calcium homeostasis is disrupted in neurodegenerative diseases because of abnormal Cav1.2 channel activity and modification of downstream Ca 2+ signaling pathways. Multiple post-translational modifications of Cav1.2 have been observed and seem to be closely related to the pathogenesis of neurodegenerative diseases. The specific molecular mechanisms by which Cav1.2 channel activity is regulated remain incompletely understood. Dihydropyridines (DHPs), which are commonly used for hypertension and myocardial ischemia, have been repurposed to treat PD and AD and show protective effects. However, further studies are needed to improve delivery strategies and drug selectivity. Better knowledge of channel modulation and more specific methods for altering Cav1.2 channel function may lead to better therapeutic strategies for neurodegenerative diseases.
No takes yet. Share an insight, caveat, or question.
Li et al. (2022) conducted a review in Neurodegenerative diseases (Alzheimer's disease, Parkinson's disease). Dihydropyridines (DHPs) was evaluated. Dihydropyridines, a class of L-type calcium channel blockers, show potential protective effects when repurposed for the treatment of Alzheimer's and Parkinson's diseases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: